Keyphrases
Nonalcoholic Steatohepatitis
100%
Interim Analysis
100%
Randomized Phase II Trial
100%
Treatment-related Adverse Events
80%
Liver
60%
Diarrhea
40%
Placebo
40%
Bile Acids
40%
Liver Injury
40%
Apical Sodium-dependent Bile Acid Transporter
40%
Clinical Trials
20%
Therapeutic Benefits
20%
Dose Effect
20%
Beneficial Effects
20%
Effective Treatment
20%
Once-daily
20%
Cholesterol
20%
Cholesterol Levels
20%
Steatosis
20%
Cirrhosis
20%
Low-density Lipoprotein Cholesterol (LDL-C)
20%
Fibrosis
20%
Tolerability
20%
Histological Analysis
20%
Lack of Efficacy
20%
Alanine Aminotransferase Level
20%
Non-alcoholic Fatty Liver Disease (NAFLD)
20%
Fatty Liver Disease
20%
Serum Cholesterol Level
20%
Acid Production
20%
Points Reduction
20%
Serum Alanine Aminotransferase
20%
Bile Acid Metabolism
20%
Reuptake
20%
Nonalcoholic Fatty Liver Disease Activity Score
20%
Target Engagement
20%
Dose Finding
20%
Lay Summary
20%
7α-hydroxy-4-cholesten-3-one
20%
Proton Density Fat Fraction
20%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Volixibat
100%
Bile Acid
35%
Adverse Event
28%
Diarrhea
14%
Placebo
14%
Side Effect
14%
Liver Injury
14%
Clinical Trial
7%
Biological Marker
7%
Low Density Lipoprotein Cholesterol
7%
Fibrosis
7%
Liver Cirrhosis
7%
Tolerability
7%
Steatosis
7%
Disease Activity Score
7%
Fatty Liver
7%
Alanine Aminotransferase
7%
Cholest 4 en 3 One
7%